Esperion Therapeutics’ (ESPR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $16.00 price objective on the biopharmaceutical company’s stock.

Other equities analysts also recently issued reports about the company. Needham & Company LLC reduced their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

Esperion Therapeutics Stock Up 2.5 %

NASDAQ ESPR opened at $2.47 on Tuesday. Esperion Therapeutics has a 52 week low of $1.16 and a 52 week high of $3.40. The company has a 50 day moving average price of $2.00 and a 200 day moving average price of $2.14. The firm has a market cap of $486.68 million, a PE ratio of -3.86 and a beta of 0.96.

Institutional Investors Weigh In On Esperion Therapeutics

Large investors have recently made changes to their positions in the stock. Wasatch Advisors LP lifted its position in Esperion Therapeutics by 38.4% during the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after acquiring an additional 6,483,070 shares during the period. Bellevue Group AG lifted its holdings in shares of Esperion Therapeutics by 136.5% during the first quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock worth $26,650,000 after purchasing an additional 5,739,800 shares during the period. Vanguard Group Inc. boosted its position in Esperion Therapeutics by 71.8% in the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock valued at $23,655,000 after buying an additional 3,688,796 shares during the last quarter. Geode Capital Management LLC increased its holdings in Esperion Therapeutics by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after buying an additional 171,609 shares during the period. Finally, Marshall Wace LLP raised its position in Esperion Therapeutics by 94.2% during the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after buying an additional 2,087,635 shares during the last quarter. 47.39% of the stock is owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.